Natural Human Interferon .BETA. Plus Ribavirin Combination Therapy in Japanese Patients Infected with Hepatitis C Virus and a High Viral Load

Katamura, Yoshio; Suzuki, Fumitaka; Akuta, Norio; Sezaki, Hitomi; Yatsuji, Hiromi; Nomura, Norihiro; Kawamura, Yusuke; Hosaka, Tetsuya; Kobayashi, Masahiro; Suzuki, Yoshiyuki; Saito, Satoshi; Arase, Yasuji; Ikeda, Kenji; Kobayashi, Mariko; Kumada, Hiromitsu

doi:10.2169/internalmedicine.47.1436

Cited by 15 publications

(22 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, IFN-betainduced mental disorders are mild compared to those induced by IFN-alpha (9). Moreover, IFN-beta could be given to elderly patients aged !70 years because of the mild side effects (10).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Combination Therapy of Natural Human Interferon Beta and Ribavirin in Chronic Hepatitis C patients

Arase

Suzuki

et al. 2011

Intern. Med.

Self Cite

View full text Add to dashboard Cite

Objective The aim of this study was to evaluate the efficacy and safety of combination therapy of natural human interferon-beta and ribavirin for patients for whom prior interferon therapy was discontinued due to depression induced by interferon-alpha. Methods Inclusion criteria were as follows; 1) HCV-genotype 1b, 2) serum HCV RNA level of !100 KIU/mL, 3) stopping the prior interferon-alpha monotherapy or combination therapy of interferon-alpha and ribavirin due to the appearance of depression. A total of 14 were enrolled in this prospective cohort study. The treatment period of combination therapy was 48 weeks. Depression states, reflected by Beck depression inventories and Hamilton depression rating scale, were assessed during combination therapy. Nonparametric procedures were employed for the analysis of background features of the patients with sustained virological response (SVR) and without SVR. A p value of <0.05 was considered to indicate a significant difference. Results Five of 14 patients (37.5%) had SVR by the intention to treat analysis. The SVR rate in patients who showed negative HCV RNA at 12 and 24 weeks after the initiation of combination therapy was 100% (4/4) and 83.3% (5/6), respectively. All of the patients continued the combination therapy owing to disappearance of severely adverse events contained the exacerbation of depression. Combination therapy did not yield a statistical difference in Beck depression inventories and Hamilton depression rating scale. Conclusion The combination therapy of IFN-beta and ribavirin is a possible therapy selection for the patients for whom interferon therapy was discontinued due to depression induced by interferon-alpha.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Combination Therapy of Natural Human Interferon Beta and Ribavirin in Chronic Hepatitis C patients

Arase

Suzuki

et al. 2011

Intern. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Katamura et al [37] reported that treatment with natural interferon-beta plus ribavirin for 48 wk leads to an SVR in 27% (3/11) of Japanese patients infected with HCV genotype 1b and a high viral load; the researchers also observed that during the treatment, the platelet count increased above the baseline after week 4 in this treatment group but not in the peginterferon-plusribavirin group (Table 1). Among the 11 with HCV G1, 7 were re-treated patients, and in 4 of 7 a transient virological response had been observed during the first cycle [37] .…”

Section: Natural Interferon-beta Plus Ribavirin For Patients With Hcvmentioning

confidence: 88%

“…Thus, it is possible that a 3-million-unit twicedaily natural interferon-beta regimen is more effective for reducing HCV RNA levels. However, the SVR rates of patients infected with HCV genotype 1b and a high viral load, who have been treated by natural interferon-beta monotherapy, are 0% to 11% [35][36][37] .…”

Section: Natural Interferon-beta For Patients With Chronic Hepatitis Cmentioning

confidence: 99%

Natural interferon-beta treatment for patients with chronic hepatitis C in Japan

Sasaki¹,

Nakamoto²,

Haga³

et al. 2015

WJH

View full text Add to dashboard Cite

“…IFN-beta was previously shown to have different signaling and biological activities from those of IFN-alpha, and achieved a higher rate of viral clearance than IFN-alpha [18][19][20][21][22][23]. The incidence of AEs such as depression, alopecia, general fatigue, and hematological changes were lower during therapies with n-IFN-beta than those with IFN-alpha [24][25][26]. In constrict to the actions of IFN-alpha, IFN-beta and IFN-lambda signaling in the liver did not become refractory during stimulation of the IFN signaling transduction pathway.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Chronic Hepatitis C with Viral-Suppression linked to Restoration of Innate-Immune Responses with Induction-Therapy with n-IFN-beta followed by Simeprevir

Kishida¹

2015

MOJI

View full text Add to dashboard Cite

Complications associated with hepatitis C virus (HCV) infection may be prevented by viral eradication. Response rates with direct-acting antivirals regimens are generally lower in chronic hepatitis C (CHC) patients who have failed to respond to previous interferon (IFN) treatments. HCV persistence in the host results from in efficient innate and adaptive immune responses. The resolution of a HCV infection may restore impairments in innate and adaptive immunities. Our previous study suggested that induction treatment with natural (n)-IFN-beta followed by maintenance treatment with n-IFN-alpha restored innate immune responses, as indicated by the significant increase of IL-12, and IL-15 and significant decrease of CXCL-8. Persistent virologic clearance and the restoration of innate immune responses with Simeprevir plus Pegylated (Peg) -IFN-alpha/ribavirin (RBV) were more likely to result in a sustained virologic response (SVR). On the basis of these findings, we conducted to treat a CHC patient with genotype 1b, a high viral load, a prior null response to IFN treatments and chronic active hepatitis with advanced fibrosis using induction therapy with n-IFN-beta followed by Simeprevir plus Peg-IFN-alpha-2b/RBV. This is the first case of difficult-to-treat CHC with genotype 1b, a high viral load, null response to previous IFN treatment and advanced hepatic fibrosis that was successfully treated with induction therapy using n-IFN-beta, which induced the viral clearance of serum HCV RNA, followed by Simeprevir plus Peg-IFN-alpha-2b/RBV. Persistent viral clearance linked to restoration of innate immune responses and SVR were achieved 12 weeks after cessation of the treatment without virologic breakthrough or relapse and sustained biochemical response. Anemia and thrombocytopenia were managed without discontinuation of the treatment. Induction therapy with n-IFN-beta followed by Simeprevir plus Peg-IFN-alpha-2b/RBV was tolerated well and only mild adverse effects were noted. It also effectively eradicated HCV infection in a difficult-to-treat CHC patient with advanced fibrosis.

show abstract

Natural Human Interferon .BETA. Plus Ribavirin Combination Therapy in Japanese Patients Infected with Hepatitis C Virus and a High Viral Load

Abstract: Objective The aim of this pilot study was to determine the safety and efficacy of natural human interferon β (nIFNβ) plus ribavirin (RBV)

Cited by 15 publications

References 25 publications

Efficacy and Safety of Combination Therapy of Natural Human Interferon Beta and Ribavirin in Chronic Hepatitis C patients

Efficacy and Safety of Combination Therapy of Natural Human Interferon Beta and Ribavirin in Chronic Hepatitis C patients

Natural interferon-beta treatment for patients with chronic hepatitis C in Japan

Treatment of Chronic Hepatitis C with Viral-Suppression linked to Restoration of Innate-Immune Responses with Induction-Therapy with n-IFN-beta followed by Simeprevir

Contact Info

Product

Resources

About